Literature DB >> 20890087

Suppression of Aurora-A oncogenic potential by c-Myc downregulation.

Shangbin Yang1, Shun He, Xiaobo Zhou, Mei Liu, Hongxia Zhu, Yihua Wang, Wei Zhang, Shuang Yan, Lanping Quan, Jingfeng Bai, Ningzhi Xu.   

Abstract

The abnormality of serine/threonine kinase Aurora-A is seen in many types of cancers. Although in physiological context it has been shown to play a vital role in cellular mitosis, how this oncogene contributes to tumorigenesis remains unclear. Here we demonstrate that Aurora-A overexpression enhances both the expression level and transcriptional activity of c-Myc. The inhibition of c-Myc expression by RNA interference significantly impaired the oncogenic potential of Aurora-A, resulting in attenuated cellular proliferation and transformation rates as well as fewer centrosomal aberrations. Furthermore, downregulation of c-Myc effectively overcame Aurora-A-induced resistance to cisplatin in esophageal cancer cells. Taken together, our results suggest an important role for c-Myc in mediating the oncogenic activity of Aurora-A, which may in turn allow for future targeting of c-Myc as a potential therapeutic strategy for tumors with Aurora-A overexpression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20890087      PMCID: PMC2992855          DOI: 10.3858/emm.2010.42.11.077

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  37 in total

1.  Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.

Authors:  F Forozan; E H Mahlamäki; O Monni; Y Chen; R Veldman; Y Jiang; G C Gooden; S P Ethier; A Kallioniemi; O P Kallioniemi
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

2.  Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells.

Authors:  Leslie C Hodges; Jennifer D Cook; Edward K Lobenhofer; Leping Li; Lee Bennett; Pierre R Bushel; C Marcelo Aldaz; Cynthia A Afshari; Cheryl Lyn Walker
Journal:  Mol Cancer Res       Date:  2003-02       Impact factor: 5.852

3.  Sustained loss of a neoplastic phenotype by brief inactivation of MYC.

Authors:  Meenakshi Jain; Constadina Arvanitis; Kenneth Chu; William Dewey; Edith Leonhardt; Maxine Trinh; Christopher D Sundberg; J Michael Bishop; Dean W Felsher
Journal:  Science       Date:  2002-07-05       Impact factor: 47.728

4.  Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma.

Authors:  Amir A Jazaeri; Karen Lu; Rosemarie Schmandt; Charles P Harris; Pulivarthi H Rao; Christos Sotiriou; G V R Chandramouli; David M Gershenson; Edison T Liu
Journal:  Mol Carcinog       Date:  2003-02       Impact factor: 4.784

5.  AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol.

Authors:  Shubha Anand; Sue Penrhyn-Lowe; Ashok R Venkitaraman
Journal:  Cancer Cell       Date:  2003-01       Impact factor: 31.743

6.  Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer.

Authors:  Donghui Li; Jijiang Zhu; Pervez F Firozi; James L Abbruzzese; Douglas B Evans; Karen Cleary; Helmut Friess; Subrata Sen
Journal:  Clin Cancer Res       Date:  2003-03       Impact factor: 12.531

Review 7.  On the role of aurora-A in centrosome function.

Authors:  Stéphanie Dutertre; Simon Descamps; Claude Prigent
Journal:  Oncogene       Date:  2002-09-09       Impact factor: 9.867

8.  Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian cells.

Authors:  Tomotoshi Marumoto; Toru Hirota; Tetsuro Morisaki; Naoko Kunitoku; Dongwei Zhang; Yasuko Ichikawa; Takashi Sasayama; Shinji Kuninaka; Tatsuyuki Mimori; Norihiko Tamaki; Masashi Kimura; Yukio Okano; Hideyuki Saya
Journal:  Genes Cells       Date:  2002-11       Impact factor: 1.891

9.  The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint.

Authors:  Silke Hauf; Richard W Cole; Sabrina LaTerra; Christine Zimmer; Gisela Schnapp; Rainer Walter; Armin Heckel; Jacques van Meel; Conly L Rieder; Jan-Michael Peters
Journal:  J Cell Biol       Date:  2003-04-21       Impact factor: 10.539

10.  Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores.

Authors:  Claire Ditchfield; Victoria L Johnson; Anthony Tighe; Rebecca Ellston; Carolyn Haworth; Trevor Johnson; Andrew Mortlock; Nicholas Keen; Stephen S Taylor
Journal:  J Cell Biol       Date:  2003-04-28       Impact factor: 10.539

View more
  18 in total

1.  Mantle cell lymphoma harboring Burkitt's-like translocations presents differential expression of aurora kinase genes compared with others 8q abnormalities.

Authors:  Fábio Morato de Oliveira; Ana Paula Nunes Rodrigues-Alves; Antônio Roberto Lucena-Araújo; Ferdinando de Paula Silva; Fernanda Borges da Silva; Roberto Passetto Falcão
Journal:  Med Oncol       Date:  2014-03-29       Impact factor: 3.064

2.  Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas.

Authors:  Norman L Lehman; James P O'Donnell; Lisa J Whiteley; Robert T Stapp; Trang D Lehman; Kathleen M Roszka; Lonni R Schultz; Caitlin J Williams; Tom Mikkelsen; Stephen L Brown; Jeffrey A Ecsedy; Laila M Poisson
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

3.  Differential expression of aurora-A kinase in T-cell lymphomas.

Authors:  Rashmi Kanagal-Shamanna; Norman L Lehman; James P O'Donnell; Megan S Lim; Daniel S Schultz; Dhananjay A Chitale; Carlos E Bueso-Ramos; L Jeffrey Medeiros; Kedar V Inamdar
Journal:  Mod Pathol       Date:  2013-02-15       Impact factor: 7.842

Review 4.  Insights into the non-mitotic functions of Aurora kinase A: more than just cell division.

Authors:  Giulia Bertolin; Marc Tramier
Journal:  Cell Mol Life Sci       Date:  2019-09-27       Impact factor: 9.261

5.  Myc, Aurora Kinase A, and mutant p53(R172H) co-operate in a mouse model of metastatic skin carcinoma.

Authors:  E C Torchia; C Caulin; S Acin; T Terzian; B J Kubick; N F Box; D R Roop
Journal:  Oncogene       Date:  2011-10-03       Impact factor: 9.867

6.  Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma.

Authors:  C Kurokawa; H Geekiyanage; C Allen; I Iankov; M Schroeder; B Carlson; K Bakken; J Sarkaria; J A Ecsedy; A D'Assoro; B Friday; E Galanis
Journal:  J Neurooncol       Date:  2016-11-05       Impact factor: 4.130

Review 7.  MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies.

Authors:  E Hessmann; G Schneider; V Ellenrieder; J T Siveke
Journal:  Oncogene       Date:  2015-06-29       Impact factor: 9.867

8.  Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma.

Authors:  James R Van Brocklyn; Jeffrey Wojton; Walter H Meisen; David A Kellough; Jeffery A Ecsedy; Balveen Kaur; Norman L Lehman
Journal:  Cancer Res       Date:  2014-08-08       Impact factor: 12.701

9.  Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1.

Authors:  Lihong Wang-Bishop; Zheng Chen; Ahmed Gomaa; Albert Craig Lockhart; Safia Salaria; Jialiang Wang; Keeli B Lewis; Jeffrey Ecsedy; Kay Washington; Robert Daniel Beauchamp; Wael El-Rifai
Journal:  Gastroenterology       Date:  2018-10-17       Impact factor: 22.682

10.  The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation.

Authors:  Xin Hong; James P O'Donnell; Clarence R Salazar; James R Van Brocklyn; Kahlil D Barnett; Dennis K Pearl; Ana C deCarvalho; Jeffrey A Ecsedy; Stephen L Brown; Tom Mikkelsen; Norman L Lehman
Journal:  Cancer Chemother Pharmacol       Date:  2014-03-14       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.